Lantern Granted Second Fast Track Designation for Triple Negative Breast Cancer Treatment
Lantern Pharma Inc., an AI-driven company focused on cancer therapies, announced that the FDA has granted Fast Track Designation to its investigational drug LP-184 for treating Triple Negative Breast Cancer (TNBC). This is the second Fast Track Designation for LP-184 in 2024, following its approval for Glioblastoma in October. Currently in a Phase 1A trial, LP-184 is being evaluated for safety and tolerability in various solid tumors, including TNBC. The drug was developed using Lantern's AI platform, RADR®, to target mechanisms in challenging cancers and refine patient selection.
Lantern Granted Second Fast Track Designation for Triple Negative Breast Cancer Treatment